Clinical trial
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma
NCT04088188 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma
- Lead sponsor
- Academic and Community Cancer Research United
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 25, 2021
- Completion date
- December 1, 2023
- Enrollment
- 8 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
advanced cholangiocarcinoma, metastatic cholangiocarcinoma, unresectable cholangiocarcinoma